Kurzfassung der KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (Leitlinie für die klinische Praxis zur Diabetesbehandlung bei chronischer Nierenkrankheit): eine Aktualisierung auf Grundlage neuer Erkenntnisse

The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline for the Management of Diabetes in Chronic Kidney Disease (CKD) is an update of the KDIGO 2020 guideline. The guideline is aimed at a broad audience of clinicians treating people with diabetes and CKD. Topics with recommendations updated based on new evidence include Chapter 1: Comprehensive Care in Patients with Diabetes and CKD, and Chapter 4: Glucose-Lowering Therapies in Patients with Type 2 Diabetes (T2 D) and CKD. The content of previous chapters on glycemic monitoring and targets in patients with diabetes and CKD (Chapter 2), lifestyle interventions in patients with diabetes and CKD (Chapter 3), and approaches to the management of patients with diabetes and CKD (Chapter 5) are considered current and have not been changed. This updated guideline was developed through a rigorous process of evidence review and evaluation. Treatment approaches and guideline recommendations are based on systematic reviews of relevant studies and assessment of evidence quality. The strength of the recommendations follows the GRADE approach (Grading of Recommendations Assessment, Development and Evaluation). The limitations of the evidence are discussed, and areas where additional research is needed are identified.